Abuse Resistant and Extended Release Formulations and Method of Use Thereof

• US 20090082466A1
• Filed: 01/29/2007
• Published: 03/26/2009
• Est. Priority Date: 01/27/2006
• Status: Active Application

• Current Assignee: Relmada Therapeutics, Inc.
• Original Assignee: Relmada Therapeutics, Inc.
• Inventors: Babul, Najib
• Application Number:
  US12/223,327
• Publication Number:
  US 20090082466A1
• Time in Patent Office: Days
• US Class Current: 514/646
• CPC Class Codes: A61K 31/33 Heterocyclic compounds
• CPC Class Codes: A61K 9/4858 Organic compounds
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds
• CPC Class Codes: A61K 9/4875 Compounds of unknown constitution, e.g. material from plants or animals oils, fats, waxes, shellac A61K9/4858

Abstract

The present invention is in the field of oral, abuse resistant pharmaceutical compositions of opioids, extended release pharmaceutical compositions of opioids and extended release abuse resistant pharmaceutical compositions of opioids and the use thereof for the treatment of pain. The present invention is also directed to extended release pharmaceutical compositions and the use thereof for preventing or minimizing the risk of opioid abuse and/or opioid toxicity from either intentional or unintentional tampering. The present invention is further directed at a method of preventing or minimizing the risk of opioid abuse and/or opioid toxicity from either intentional or unintentional tampering.

Claims

1-160. -160. (canceled)

161. An abuse deterrent monolithic solidified oral dosage form prepared by a thermal process comprising the following material:

(a) a therapeutically effective amount of opioid agonist or a pharmaceutically acceptable salt thereof or a mixture thereof;

(b) one or more compounds selected from the group consisting of;

(i) hydrogenated Type I or Type II vegetable oils;

(ii) polyoxyethylene stearates and distearates;

(iii) glycerol monostearate;

(iv) poorly water soluble, high melting point (mp=45 to 100°

C.) waxes; and

(c) one or more additional pharmaceutically acceptable excipients, wherein the material are substantially uniformly dispersed, wherein abuse-deterrent and extended-release properties are simultaneously provided, wherein, upon physical tampering of the dosage form, the in-vitro release rate by weight of the opioid agonist from the dosage form over the first hour when measured by the USP paddle method at 100 rpm in 900 mL aqueous buffer at a pH of between 1.6 and 7.2 at 37°

C. is less than for an immediate release form of the opioid agonist, and wherein, upon physical tampering of the dosage form, the in-vivo dose-normalized C_max upon first administration of the opioid agonist from the dosage form is less than for an immediate release form of the opioid agonist.

167. A claim according to claim 161 and claim 162, wherein the dosage form is prepared by liquid filling the material into capsules.

168. A claim according to claim 161 and claim 162, wherein the dosage form deters surreptitious adulteration of a beverage and surreptitious intoxication.

169. A claim according to claim 161 and claim 162, wherein the dosage form reduces or prevents the toxicity of the opioid agonist due to dose dumping when the dosage form is co-ingested with alcohol, wherein the ratio of the mean opioid agonist C_max upon first administration of the intact dosage form concurrently with 240 mL of 40% ethanol to the mean C_max after first administration of the intact dosage form without 240 mL of 40% ethanol, each administered orally to fasted subjects, is not more than about 4:

1.

170. A claim according to claim 161 and claim 162, wherein the opioid agonist is the most water soluble commercially available pharmaceutically acceptable salt.

171. A claim according to claim 161 and claim 162, wherein the dosage form has diameter of more than 5 mm.

172. A claim according to claim 161 and claim 162, wherein the molar amount of the compound is at least 15-fold greater than the molar amount of the opioid agonist or its pharmaceutically acceptable salt, inclusive of it water of hydration (e.g., anhydrous, monohydrate, dihydrate) in the dosage form.

173. A claim according to claim 161 and claim 162, wherein the material substantially forms a single phase in the dosage form and/or wherein the dosage form is not in the form of an aggregate or composite of individual solid particulates.

174. A claim according to claim 161 and claim 162, wherein the material comprising the opioid agonist, the compound and pharmaceutically acceptable excipients are prepared or manufactured in situ (i.e., in a single reaction and mixing vessel) prior to transfer to a filling machine for final encapsulation.

175. A claim according to claim 161 and claim 162, providing an in-vitro release rate by weight of an opioid agonist of (i) less than about 35% after 30 minutes of agitation of the intact dosage form on an orbital shaker at 240 cycles/min in 18 mL of a 0.1 N HCl solution in a 60 mL amber bottle, said release less than about 60% following the addition of 12 mL of 90% to 95% ethanol and further agitation for 180 minutes on an orbital shaker at 240 cycles/min, each at 25°

C.;

(ii) less than about 50% after 30 minutes of agitation of the tampered dosage form on an orbital shaker at 240 cycles/min in 18 mL of a 0.1 N HCl solution in a 60 mL amber bottle, said release less than about 70% following the addition of 12 mL of ethanol 90% to 95% and further agitation for 180 minutes on an orbital shaker at 240 cycles/min, each at 25°

C.; and

(iii) between 0% and about 60% at 1 hour, between about 0% and about 80% at 2 hours, between about 1% and about 95% at 4 hours and between about 10% and about 100% at 8 hours, when measured by the USP paddle method at 100 rpm in 900 mL aqueous buffer at a pH of between 1.6 and 7.2 at 37°

C.

176. A claim according to claim 161 and claim 162, wherein (i) the ratio of the mean opioid agonist C_max upon first administration after tampering to the mean C_max after first administration of an intact dosage form is not more than about 6:

1;

(ii) the ratio of the mean opioid agonist AUC_0-1 upon first administration after tampering to the mean AUC_0-1 after first administration of an intact dosage form is not more than about 6;

1;

(iii) the ratio of the mean opioid agonist T_max upon first administration of an intact dosage form to the mean T_max after first administration of a tampered dosage form is not more than about 6;

1; and

(iv) the ratio of the mean opioid agonist C_max upon first administration of the intact dosage form concurrently with 240 mL of 40% ethanol to the mean C_max after first administration of the intact dosage form without 240 mL of 40% ethanol, each to fasted subjects, is not more than about 4;

1.

177. A claim according to claim 161 and claim 162, wherein:

(i) the mean ratio of the time to meaningful pain relief after administration of the intact dosage form to a human patient to the time to meaningful pain relief after administration of the tampered dosage form is less than 6;

1;

(ii) mean ratio of the peak pain intensity difference score after administration of the tampered dosage form to a human patient to the peak pain intensity difference score after administration of the intact dosage form is less than 6;

1;

(iii) the mean ratio of the number needed to harm (NNH) due to moderate or severe nausea after administration of the tampered dosage form to opioid naï

ve healthy subjects to the NNH due to moderate or severe nausea after administration of the intact dosage form of less than 6;

1;

(iv) the mean ratio of the drug liking score in drug abusers and recreational drug users without pain after administration of the tampered dosage form to the drug liking score after administration of the of the intact dosage form is less than 6;

1; and

(v) the mean ratio of the drug effect score in drug abusers and recreational drug users without pain after administration of the tampered dosage form to the drug effect score after administration of the intact dosage form is less than 6;

1.

178. A claim according to claim 161 and claim 162, wherein the compounds are further selected form the group comprising:

glyceryl behenate, hydrogenated vegetable oil, hydrogenated cottonseed oil, hydrogenated palm oil, hydrogenated soybean oil, hydrogenated coconut oil, their respective esters and derivatives.

179. A claim according to claim 161 and claim 162, wherein the opioid agonist is selected from the group comprising (i) alfentanil, anileridine, buprenorphine, brifentanil, butorphanol, carfentanil, codeine, dextromoramide, dezocine, dihydrocodeine, fentanyl, heroin, hydrocodone, hydromorphone, ketobemidone, levorphanol, levomethadone, lofentanil, meperidine, meptazinol, methadone, 4-methoxymethylfentanyl, 3-methylfentanil, mirfentanil, morphine, morphine-6-glucuronide, nalbuphine, ohmefentanyl, O-desmethyl tramadol, opium, oxycodone, oxymorphone, pentazocine, phenazocine, propiram, propoxyphene, racemorphan, remifentanil, sulfentanil, tapentadol, trefentanil, tramadol, tilidine;

and (ii) any opioid agonist belonging to the phenanthrene, morphinan, benzomorphan, methadone, phenylpiperidine, propionanilide 4-anilidopiperidine, 4-aryl piperidines and 4-heteroarylpiperidines class, and their pharmaceutically acceptable salts, prodrugs, esters, polymorphs, hydrates and metabolites, as racemates or an individual diastereoisomers or enantiomeric isomers thereof or mixtures thereof.

180. A method of preparing an abuse deterrent monolithic solidified oral dosage form by a thermal process comprising the material in claim 161 and claim 162, wherein the material are substantially uniformly dispersed, wherein abuse-deterrent and extended-release properties are simultaneously provided, wherein, upon physical tampering of the dosage form, the in-vitro release rate by weight of the opioid agonist from the dosage form over the first hour when measured by the USP paddle method at 100 rpm in 900 mL aqueous buffer at a pH of between 1.6 and 7.2 at 37°

C. is less than for an immediate release form of the opioid agonist, wherein, upon physical tampering of the dosage form, the in-vivo dose-normalized C_max upon first administration of the opioid agonist from the dosage form is less than for an immediate release form of the opioid agonist and wherein, in the case of material from claim 162, the thixotrope and release rate modifier provide further abuse deterrence.

162. An abuse deterrent monolithic solidified oral dosage form prepared by a thermal process comprising the following material:

(a) a therapeutically effective amount of opioid agonist or a pharmaceutically acceptable salt thereof or a mixture thereof;

(b) one or more compounds selected from the group consisting of;

(i) hydrogenated Type I or Type II vegetable oils;

(ii) polyoxyethylene stearates and distearates;

(iii) glycerol monostearate;

(iv) poorly water soluble, high melting point (mp=45 to 100°

C.) waxes; and

(c) at least one pharmaceutically acceptable excipient selected from the group comprising a thixotrope and a release rate modifier, wherein the thixotrope and release rate modifier provide further abuse deterrence, wherein the material are substantially uniformly dispersed, wherein abuse-deterrent and extended-release properties are simultaneously provided, wherein, upon physical tampering of the dosage form, the in-vitro release rate by weight of the opioid agonist from the dosage form over the first hour when measured by the USP paddle method at 100 rpm in 900 mL aqueous buffer at a pH of between 1.6 and 7.2 at 37°

C. is less than for an immediate release form of the opioid agonist, and wherein, upon physical tampering of the dosage form, the in-vivo dose-normalized C_max upon first administration of the opioid agonist from the dosage form is less than for an immediate release form of the opioid agonist.

163. A claim according to claim 162, wherein the dosage form consists of (a) a therapeutically effective amount of opioid agonist or a pharmaceutically acceptable salt thereof or a mixture thereof;

(b) one or more compounds selected from the group consisting of;

(i) hydrogenated Type I or Type II vegetable oils;

(ii) polyoxyethylene stearates and distearates;

(iii) glycerol monostearate;

(iv) poorly water soluble, high melting point (mp=45 to 100°

C.) waxes; and

(c) a thixotrope.

164. A claim according to claim 162, wherein the dosage form consists of (a) a therapeutically effective amount of opioid agonist or a pharmaceutically acceptable salt thereof or a mixture thereof;

(b) one or more compounds selected from the group consisting of;

(i) hydrogenated Type I or Type II vegetable oils;

(ii) polyoxyethylene stearates and distearates;

(iii) glycerol monostearate;

(iv) poorly water soluble, high melting point (mp=45 to 100°

C.) waxes; and

(c) a release rate modifier.

165. A claim according to claim 162, wherein the dosage form consists of (a) a therapeutically effective amount of opioid agonist or a pharmaceutically acceptable salt thereof or a mixture thereof;

(b) one or more compounds selected from the group consisting of;

(i) hydrogenated Type I or Type II vegetable oils;

(ii) polyoxyethylene stearates and distearates;

(iii) glycerol monostearate;

(iv) poorly water soluble, high melting point (mp=45 to 100°

C.) waxes;

(c) a thixotrope; and

(d) a release rate modifier.

166. A claim according to claim 162, wherein the thixotrope is silicon dioxide or a mixture of silicon dioxide and aluminum oxide and the release rate modifier is hydroxypropyl methylcellulose.